Rheumatic Disease Clinics of North America is a premier journal published by W B Saunders Co-Elsevier Inc, dedicated to advancing the field of rheumatology through comprehensive and impactful research. With an ISSN of 0889-857X and an E-ISSN of 1558-3163, this esteemed publication has been disseminating knowledge since its inception in 1987, and continues to guide clinicians and researchers alike through its insightful articles and case studies. Positioned in the 2023 Q2 quartile for Rheumatology, it ranks #31 out of 73 journals in the Scopus category of Medicine _ Rheumatology, reflecting a commendable impact factor and relevance in the academic community. Although it does not offer open access options, the journal ensures that subscribers have access to cutting-edge research and reviews that address contemporary challenges and advancements in rheumatic disease. With its authoritative content, Rheumatic Disease Clinics of North America serves as a vital resource for those striving to improve patient care and clinical outcomes in the ever-evolving landscape of rheumatology research.

Journal of Rheumatic Diseases, published by the Korean College of Rheumatology, stands as a pivotal platform in the field of rheumatology, contributing significantly to the advancement of knowledge and clinical practice since its inception. With an impact factor reflecting its esteemed position in the academic community, this open-access journal promotes accessibility to high-quality research, ensuring that groundbreaking discoveries are reachable to all stakeholders in the realm of rheumatic diseases. The journal has maintained its commitment to quality, evidenced by its ranking in the Q3 category for Rheumatology in 2023, and its presence among the top quartiles of medical research. Focusing on innovative therapeutic approaches, emerging diagnostic techniques, and comprehensive reviews, the Journal of Rheumatic Diseases seeks to foster collaboration and dialogue among researchers, clinicians, and students alike. For accessibility, the journal offers numerous articles since its transition to open access in 2017, thereby facilitating research dissemination across the globe. As it converges over the years from 2019 to 2024, the journal promises to be instrumental in shaping the future of rheumatic disease research, inviting contributions that inspire new frontiers in this essential field.

The International Journal of Rheumatology, published by HINDAWI LTD, serves as a vital resource for researchers and practitioners in the fields of rheumatology and immunology. Since its inception in 2009 as an Open Access journal, it has aimed to disseminate high-quality, peer-reviewed research to foster advancements in the understanding and treatment of rheumatic diseases. With an ISSN of 1687-9260 and E-ISSN of 1687-9279, the journal has become increasingly relevant, achieving a respectable Q3 ranking in both the Immunology and Rheumatology categories in 2023, and earning a Scopus rank of #27 out of 73 in Medicine Rheumatology. The journal's commitment to excellence is reflected in its wide-ranging scope, addressing current trends and innovations through empirical studies, reviews, and clinical insights. Its global readership, based in the United States and beyond, highlights the journal's importance in shaping the discourse within rheumatological research. As it converges through the years from 2010 to 2024, the International Journal of Rheumatology continues to be a cornerstone for sharing groundbreaking findings and fostering collaboration in the rheumatic disease community.

Lupus Science & Medicine is a leading open-access journal published by the BMJ Publishing Group, dedicated to advancing the understanding and treatment of lupus and related autoimmune diseases. Since its establishment in 2014, the journal has fostered an academic environment for researchers, healthcare professionals, and students, providing a platform for high-quality, evidence-based studies. With a notable impact in the fields of immunology and rheumatology, it currently holds a Q1 ranking in Rheumatology and Medicine (miscellaneous) and Q2 in Immunology, reflecting its significant contribution to these vital areas of medical research. The journal is indexed in Scopus, with a commendable rank in the 67th percentile for Rheumatology, making it a valuable resource for those seeking the latest insights into lupus management and treatment. The journal emphasizes the importance of open access, ensuring that research findings are widely available to enhance global knowledge and collaboration in the fight against lupus.

The Scandinavian Journal of Rheumatology, published by Taylor & Francis Ltd, is a prestigious peer-reviewed journal dedicated to advancing research in the fields of rheumatology, immunology, and related disciplines. With an ISSN of 0300-9742 and an E-ISSN of 1502-7732, this journal has established itself as a vital platform for disseminating significant findings and innovative approaches in the management of rheumatic diseases since its inception in 1959. As a recognized scholarly outlet, it currently resides within the Q2 category for Medicine (miscellaneous) and ranks #39 out of 73 in Rheumatology according to the 2023 Scopus assessments. This reflects the journal's commitment to high-quality research and its relevance in the scientific community. Although it does not provide Open Access options, the journal's rigorous selection process ensures that only the most impactful research reaches its audience, making it a crucial resource for researchers, clinicians, and students engaged in the exploration of rheumatological and immunological challenges. The journal's broad scope encompasses ongoing studies, clinical trials, and reviews that aim to enhance understanding and treatment of rheumatic conditions, promoting collaboration and knowledge-sharing among professionals in the field.

Reumatologia Clinica is a distinguished journal dedicated to the field of Rheumatology, published by Elsevier España SLU. With its ISSN of 1699-258X and E-ISSN 1885-1398, the journal aims to disseminate pivotal research findings and clinical studies from 2005 to 2024, spotlighting advancements in the understanding and treatment of rheumatic diseases. Based in Barcelona, Spain, it plays a vital role in the academic community, ranking in the Q3 category for Rheumatology as of 2023, with a Scopus ranking of #44 out of 73, placing it in the 40th percentile. Although it operates under a traditional access model, the journal is committed to academic excellence, providing researchers, healthcare professionals, and students with invaluable insights that drive the field forward. Reumatologia Clinica serves as an essential resource for those looking to deepen their knowledge and contribute to the evolving landscape of rheumatologic research.

Reumatismo is a distinguished Open Access journal dedicated to the field of rheumatology, published by PAGEPRESS PUBL since 2001. With a rich history dating back to 1952, this journal has been pivotal in disseminating vital research on rheumatic diseases and related disorders. Based in Italy, Reumatismo has earned a reputation for its quality and relevance, achieving a Q3 category ranking in the 2023 Scopus metrics for Rheumatology, reflecting its significant contributions to the field. The journal is committed to providing a platform for the latest scientific developments and clinical innovations, thus aiding researchers, healthcare professionals, and students striving to enhance understanding and treatment of rheumatic conditions. For those seeking to access comprehensive research articles and studies, Reumatismo boasts an open access policy, ensuring that knowledge is freely available to all, fostering collaboration and advancement in rheumatology worldwide.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY is a prestigious journal published by CLINICAL & EXPER RHEUMATOLOGY, dedicated to advancing the field of rheumatology and immunology. With a rich history dating back to 1983, the journal serves as a critical platform for researchers, clinicians, and professionals seeking to disseminate and discuss innovative findings in these rapidly evolving areas. Featuring an impressive Q2 ranking in both Immunology and Allergy, as well as Rheumatology, this journal is recognized for its high-quality contributions, placing it among the top tier of academic publications. Operating without an open access model, CLINICAL AND EXPERIMENTAL RHEUMATOLOGY is headquartered in Pisa, Italy, and publishes articles that undergo rigorous peer review to ensure excellence in research. This journal is an invaluable resource for those dedicated to improving patient outcomes through evidence-based practice in rheumatology, immunology, and related fields.

Clinical Medicine Insights-Arthritis and Musculoskeletal Disorders, published by SAGE PUBLICATIONS LTD, is an esteemed open-access journal dedicated to advancing knowledge in the field of rheumatology and related immunological disorders. Since its inception in 2008, the journal has provided a platform for researchers and clinicians from around the world to disseminate cutting-edge studies and insights into arthritis and musculoskeletal conditions. Based in New Zealand, this journal has maintained a commendable standing in academic circles, evidenced by its Q3 quartile rankings in both Immunology and Allergy and Rheumatology categories for 2023, alongside respectable Scopus rankings. The journal serves as a vital resource for healthcare professionals, researchers, and students, facilitating enhanced understanding and treatment of musculoskeletal disorders through high-quality research and peer-reviewed articles. With a focus on fostering interdisciplinary collaboration and innovation in the field, Clinical Medicine Insights-Arthritis and Musculoskeletal Disorders is essential reading for those committed to improving patient outcomes and advancing scientific knowledge.

BMC Rheumatology is a vital open-access journal that has been disseminating high-quality research in the field of rheumatology since its inception in 2017. Published by Springer Nature, this journal provides a platform for original research, reviews, and clinical studies that advance the understanding and treatment of rheumatic diseases. With a commendable impact factor and ranked in the second quartile (Q2) for Rheumatology as of 2023, BMC Rheumatology exemplifies expertise, contributing significantly to the medical community's dialogue. Researchers, professionals, and students will find valuable insights within its pages, as it caters to a diverse audience through its commitment to open-access publishing, facilitating knowledge sharing without barriers. Based in the United Kingdom and indexed in Scopus, the journal continues to thrive with a steady convergence of academic excellence through 2024, making it an indispensable resource for those dedicated to advancing rheumatological science.